EUVIMEDEUVIMED entdecken
Crossref

Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer

Farukh A Durrani, Joseph Cacaccio, William Potter, Mykhaylo Dukh, Mehrgan Ghazaeian, Ahmed A Hussein, Omar M Ibrahim, Pawel Kalinski, Paras N Prasad iD, Heinz Baumann, Khurshid A Guru iD, Ravindra K Pandey iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Farukh A Durrani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York14263, United States. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cyclooxygenase 2 Inhibitors, Photochemotherapy, Photosensitizing Agents. Die Arbeit nennt 58 Literaturangaben. Gefördert von: NCI NIH HHS, Roswell Park Comprehensive Cancer Center, Photolitec, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among the photosensitizers (PSs) developed in our laboratory, 3-(1′-hexyloxy) ethyl-3-devinyl pyropheophorbide-a (HPPH) is undergoing Phase-II multicenter clinical trials for the treatment of head and neck and esophageal cancers. The PS exhibits absorption at 665 nm (in vivo) and shows desired pharmacokinetics with limited skin phototoxicity in patients, compared to FDA-approved Photofrin. This study determined the effect of HPPH-PDT in vitro and in vivo on human bladder cancer (BCa) tissue grown in immune-deficient mice. We observed high tumor uptake/retention of HPPH at 24 h post injection. The anticancer activity of HPPH-PDT was associated with undesirable induction of COX-2, the key enzyme enhancing the production of prostaglandin E2 (PGE2), a pathway we previously found accompanying tumors associated with immune suppression and tumor progression. Combination of COX-2 inhibition with PDT or with BCG-immunotherapy showed an improved rate of tumor cures. Hence, HPPH-PDT in combination with COX-2 inhibitors not only reduces the expression of COX-2, IL-6, VEGF, and PGE2 but also enhances long-term tumor cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCyclooxygenase 2 InhibitorsPhotochemotherapyPhotosensitizing AgentsBCG VaccineImmunotherapyPorphyrinsAnimalsHumansMiceCyclooxygenase 2Cell Line, TumorFemaleDinoprostoneChlorophyll

Stichwörter der Autor:innen

Bacillus Calmette-GuerinFood and Drug Administrationbladder cancercyclooxygenase-2photodynamic therapyprostaglandin E2vascular endothelial growth factor

Substanzen

Cyclooxygenase 2 InhibitorsPhotosensitizing AgentsBCG VaccineCyclooxygenase 22-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-aDinoprostonePorphyrinsChlorophyll

Autor:innen und Institutionen

  • Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York14263, United States.
  • Institute of Lasers, Photonics and Bio-photonics, University of Buffalo, Buffalo, New York14221, United States.
  • Photolitec, LLC, Buffalo, New York14051, United States.
  • Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York14263, United States.
  • Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York14263, United States.
  • Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York14263, United States.

ORCID-Profile: Paras N Prasad, Khurshid A Guru, Ravindra K Pandey

Förderung

  • NCI NIH HHS
  • Roswell Park Comprehensive Cancer Center
  • Photolitec, LLC
  • National Cancer Institute

Zitieren

APA

Durrani, F. A., Cacaccio, J., Potter, W., Dukh, M., Ghazaeian, M., Hussein, A. A., Ibrahim, O. M., Kalinski, P., Prasad, P. N., Baumann, H., Guru, K. A., & Pandey, R. K. (2026). Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01678

Vancouver

Durrani FA, Cacaccio J, Potter W, Dukh M, Ghazaeian M, Hussein AA, et al. Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01678

BibTeX
@article{Durrani2026,
  author = {Durrani, Farukh A and Cacaccio, Joseph and Potter, William and Dukh, Mykhaylo and Ghazaeian, Mehrgan and Hussein, Ahmed A and Ibrahim, Omar M and Kalinski, Pawel and Prasad, Paras N and Baumann, Heinz and Guru, Khurshid A and Pandey, Ravindra K},
  title = {Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01678}
}
Kostenlos starten →